Displaying 1 - 12 of 34
Metabolism, Alcohol & Toxicity

Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Discussion and Q&A

Webcasts
View
Metabolism, Alcohol & Toxicity

Introduction

Webcasts
View
Metabolism, Alcohol & Toxicity

NASH: a growing unmet therapeutic need

Webcasts
View
Metabolism, Alcohol & Toxicity

The underestimated role of thyroid hormone pathway in the pathophysiology of NASH

Webcasts
View
Metabolism, Alcohol & Toxicity

Key take home messages and close

Webcasts
View
Metabolism, Alcohol & Toxicity

Welcome and introduction

Webcasts
View
Metabolism, Alcohol & Toxicity

Tools for early detection of metabolic risk in MAFLD

Webcasts
View
Metabolism, Alcohol & Toxicity

Insights from the SIRIUS project – a population-wide liver disease screening program in Slovakia

Webcasts
View
Displaying 1 - 12 of 34